Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival

J Am Coll Surg. 2015 May;220(5):940-50. doi: 10.1016/j.jamcollsurg.2015.01.056. Epub 2015 Feb 14.

Abstract

Background: The regional impact of care at a National Cancer Institute Comprehensive Cancer Center (NCI-CCC) on adherence to National Comprehensive Cancer Network (NCCN) ovarian cancer treatment guidelines and survival is unclear.

Study design: We performed a retrospective population-based study of consecutive patients diagnosed with epithelial ovarian cancer between January 1, 1996 and December 31, 2006 in southern California. Patients were stratified according to care at an NCI-CCC (n = 5), non-NCI high-volume hospital (≥ 10 cases/year, HVH, n = 29), or low-volume hospital (<10 cases/year, LVH, n = 158). Multivariable logistic regression and Cox-proportional hazards models were used to examine the effect of NCI-CCC status on treatment guideline adherence and ovarian cancer-specific survival.

Results: A total of 9,933 patients were identified (stage I, 22.8%; stage II, 7.9%; stage III, 45.1%; stage IV, 24.2%), and 8.1% of patients were treated at NCI-CCCs. Overall, 35.7% of patients received NCCN guideline adherent care, and NCI-CCC status (odds ratio [OR] 1.00) was an independent predictor of adherence to treatment guidelines compared with HVHs (OR 0.83, 95% CI 0.70 to 0.99) and LVHs (OR 0.56, 95% CI 0.47 to 0.67). The median ovarian cancer-specific survivals according to hospital type were: NCI-CCC 77.9 (95% CI 61.4 to 92.9) months, HVH 51.9 (95% CI 49.2 to 55.7) months, and LVH 43.4 (95% CI 39.9 to 47.2) months (p < 0.0001). National Cancer Institute Comprehensive Cancer Center status (hazard ratio [HR] 1.00) was a statistically significant and independent predictor of improved survival compared with HVH (HR 1.18, 95% CI 1.04 to 1.33) and LVH (HR 1.30, 95% CI 1.15 to 1.47).

Conclusions: National Cancer Institute Comprehensive Cancer Center status is an independent predictor of adherence to ovarian cancer treatment guidelines and improved ovarian cancer-specific survival. These data validate NCI-CCC status as a structural health care characteristic correlated with superior ovarian cancer quality measure performance. Increased access to NCI-CCCs through regional concentration of care may be a mechanism to improve clinical outcomes.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • California
  • Cancer Care Facilities / standards*
  • Cancer Care Facilities / statistics & numerical data
  • Carcinoma, Ovarian Epithelial
  • Chemotherapy, Adjuvant
  • Female
  • Guideline Adherence / statistics & numerical data*
  • Hospitals, High-Volume / standards
  • Hospitals, High-Volume / statistics & numerical data
  • Hospitals, Low-Volume / standards
  • Hospitals, Low-Volume / statistics & numerical data
  • Humans
  • Hysterectomy
  • Logistic Models
  • Middle Aged
  • National Cancer Institute (U.S.) / standards*
  • Neoplasms, Glandular and Epithelial / mortality
  • Neoplasms, Glandular and Epithelial / therapy*
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / therapy*
  • Ovariectomy
  • Practice Guidelines as Topic
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome
  • United States
  • Young Adult

Substances

  • Antineoplastic Agents